Is inflammation a direct response to dsDNA breaks? Mutat Res Fund Mol Mech Mutagen808: 48-52.
Prevention of chemotherapy toxicity by agents that neutralize or degrade cell-free chromatin. Annals of Oncology. 28: 2119-2127. doi: 10.1093/annonc/mdx318.
Cell-free chromatin from dying cancer cells integrate into genomes of bystander healthy cells to induce DNA damage and inflammation. Cell Death Disc. 3: 17015; doi: 10.1038/cddiscovery.2017.15.
Physical shearing imparts biological activity to DNA and ability to transmit itself horizontally across species and kingdom boundaries. BMC Mol Biol. 18: 21. doi: 10.1186/s12867-017-0098-8.
Evidence for cell-free nucleic acids as continuously arising endogenous DNA mutagens. Mutat Res.793-794: 15-21. (doi: 10.1016/j.mrfmmm.2016.10.002).
Circulating nucleic acids: a new class of physiological mobile genetic elements. F1000Research. 4: 924 (doi: 10.12688/f1000research.7095.1).
A paradoxical synergism between Resveratrol and copper (II) with respect to degradation of DNA and RNA. F1000Research. 4: 1145 (doi: 10.12688/f1000research.7202.1).
Circulating nucleic acids damage DNA of healthy cells by integrating into their genomes. J Biosci.40(1): 91-111.
Effect of VIA screening by primary health workers: randomized controlled study in Mumbai, India. J Natl Cancer Inst. 106(3):dju009. doi: 10.1093/jnci/dju009.
Pullulan-histone antibody nanoconjugates for the removal of chromatin fragments from systemic circulation. Biomaterials. 34(27): 6328-38. doi:10.1016/j.biomaterials.2013.05.019.
Mittra I, Müller B, Nicolucci A, Peralta O, Pernas F, Petruzelka L, Pienkowski T, Radhika R, Rajan B, Rubach MT, Tort S, Urrútia G, Valentini M, Wang Y, Peto R; Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group. 2013. Long-term effect
Nucleic acids in circulation: Are they harmful to the host? J. Biosci. 37(2): 301-312.
Single-injection depot progesterone before surgery and survival in women with operable breast cancer: a randomized controlled trial. J Clin Oncol.29(21): 2845-51. doi:10.1200 / JCO.2010.33.0738.
A cluster randomized, controlled trial of breast and cervix cancer screening in Mumbai, India: methodology and interim results after three rounds of screening. Int J Cancer. 126(4): 976-84. doi: 10.1002/ijc.24840.
Why is modern medicine stuck in a rut? Perspect Biol Med. 52(4): 500-17. doi: 10.1353/pbm.0.0131.
Clinical cancer trials in developing countries. Lancet. 349(9047): 290.
Multicentricity and recurrence of breast cancer. Lancet. 349(9046): 208
Oestrogen increases S-phase fraction and oestrogen and progesterone receptors in human cervical cancer in vivo. Br J Cancer. 75(4): 554-8.
A comparative study of detection of p53 mutations in human breast cancer by flow cytometry, single-strand conformation polymorphism and genomic sequencing. Br J Cancer. 74(8): 1181-7.
Multicentricity of breast cancer: whole-organ analysis and clinical implications. Br J Cancer. 74(5): 820-4.
Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12000 randomised children. Lancet. 347(9018): 1783-8.
Breast screening: the case for physical examination without mammography. Lancet. 343(8893): 342-4.
A meta-analysis of reported correlations between prognostic factors in breast cancer: does axillary lymph node metastasis represent biology or chronology? Eur J Cancer. 27(12): 1574-83.
Early detection of breast cancer in developing countries. Lancet.1(8640): 719-20.
Somatomedins and proteolytic bioactivation of prolactin and growth hormone. Cell. 38(2): 347-8.
1980. A novel "cleaved prolactin" in the rat pituitary: Part II. In vivo mammary mitogenic activity of its N-terminal 16K moiety.Biochem Biophys Res Commun. 95(4): 1760-7.
A novel "cleaved prolactin" in the rat pituitary: part I. Biosynthesis, characterization and regulatory control. Biochem Biophys Res Commun. 95(4): 1750-9.
Thyroid and other autoantibodies in British and Japanese women: an epidemiological study of breast cancer. Br Med J. 1(6004): 257-9.
Hypothalamic-pituitary-prolactin axis in breast cancer. Lancet. 1(7863): 889-91.
Hypothalamic-pituitary-thyroid axis in breast cancer. Lancet. 1(7863): 885-9.
Mammotropic effect of prolactin enhanced by thyroidectomy. Nature. 248(448): 525-6.